Piper Sandler Maintains Neutral on Akoya Biosciences, Lowers Price Target to $1.65

Benzinga · 04/14 14:55
Piper Sandler analyst David Westenberg maintains Akoya Biosciences (NASDAQ:AKYA) with a Neutral and lowers the price target from $2.4 to $1.65.